Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: J Neurooncol. 2015 May 17;124(1):13–22. doi: 10.1007/s11060-015-1807-0

Fig. 3.

Fig. 3

a ROS detection in live U87MGEGFRvIII cells (20 × 103/well) after treatment with control (PBS), IONPs (0.3mg/ml), cetuximab (0.3mg/ml) and cetuximab-IONPs (0.3mg/ml) and subsequent single IR dose of 10Gy 24 h post-treatment. Cells were stained 3 h post IR for ROS detection with 5-(and-6)-carboxy-2′,7′ dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA), a marker for ROS detection in live cells. Green: ROS, Blue: Hoechst 33342. b. Left: Induction of ROS in U87MGEGFRvIII cells by tert-butyl hydroperoxide (TBHP), an inducer of ROS production (positive control). Right: U87MGEGFRvIII stained for baseline ROS expression with 5-(and-6)-carboxy-2′,7′ dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA), a marker for ROS detection in live cells (negative control). Green: ROS, Blue: Hoechst 33342